Campanella Toni A, Gallagher Jason C
Department of Pharmacy, Jefferson Health Northeast, Philadelphia, PA, USA.
Department of Pharmacy Practice, Temple University, Philadelphia, PA, USA.
Infect Drug Resist. 2020 Nov 25;13:4297-4308. doi: 10.2147/IDR.S224228. eCollection 2020.
Imipenem-relebactam (I-R) is a novel beta-lactam/beta-lactamase inhibitor combination given with cilastatin. It is indicated for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired or ventilator-associated bacterial pneumonia. A literature search was completed to evaluate the evidence to date of I-R. I-R has in vitro activity against multidrug-resistant organisms including carbapenem-resistant and extended-spectrum beta-lactamase and carbapenem-resistant Enterobacterales. It was granted FDA approval following the promising results of two phase II clinical trials in patients with complicated urinary tract infections and complicated intra-abdominal infections. The most common adverse drug events associated with I-R were nausea (6%), diarrhea (6%), and headache (4%). I-R is a new beta-lactam/beta-lactamase inhibitor combination that will be most likely used for patients with multidrug-resistant gram-negative infections in which there are limited or no available alternative treatment options.
亚胺培南-瑞来巴坦（I-R）是一种与西司他丁联用的新型β-内酰胺类/β-内酰胺酶抑制剂组合。它适用于治疗复杂性尿路感染、复杂性腹腔内感染以及医院获得性或呼吸机相关性细菌性肺炎。已完成一项文献检索以评估迄今为止关于I-R的证据。I-R对包括耐碳青霉烯类、产超广谱β-内酰胺酶以及耐碳青霉烯类肠杆菌科细菌在内的多重耐药菌具有体外活性。在两项针对复杂性尿路感染和复杂性腹腔内感染患者的II期临床试验取得有前景的结果后，它获得了美国食品药品监督管理局（FDA）的批准。与I-R相关的最常见不良药物事件为恶心（6%）、腹泻（6%）和头痛（4%）。I-R是一种新型β-内酰胺类/β-内酰胺酶抑制剂组合，极有可能用于多重耐药革兰氏阴性菌感染且可供选择的治疗方案有限或没有的患者。
